TABLE 2.
Univariate and multivariate analysis for progression‐free survival
| Median PFS (months) | Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Factor | N | HR | 95% CI | p‐value | HR | 95% CI | p‐value | ||
| TTF‐1 | Positive | 83 | 5.4 | ||||||
| Negative | 25 | 1.6 | 2.42 | 1.46–3.90 | <0.001 | 2.09 | 1.19–3.57 | 0.011 | |
| PD‐L1 TPS | ≥50% | 60 | 8.4 | ||||||
| <50% | 48 | 2.3 | 1.68 | 1.10–2.57 | 0.017 | 1.13 | 0.64–2.03 | 0.67 | |
| Smoking status | Current or former smoker | 86 | 4.5 | ||||||
| Never smoker | 20 | 1.6 | 1.95 | 1.12–3.21 | 0.020 | 1.59 | 0.85–2.86 | 0.14 | |
| ECOG PS | 0–1 | 85 | 5.4 | ||||||
| ≥2 | 23 | 1.0 | 5.38 | 3.11–9.05 | <0.001 | 6.49 | 3.60–11.42 | <0.001 | |
| Treatment line | First‐line | 55 | 9.3 | ||||||
| Second or later | 53 | 2.8 | 1.65 | 1.08–2.54 | 0.020 | 1.64 | 0.91–2.92 | 0.095 | |
| EGFR mutation | Wild‐type | 94 | 3.3 | ||||||
| Mutant | 12 | 2.8 | 1.20 | 0.60–2.16 | 0.59 | 1.25 | 0.61–2.58 | 0.54 | |
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; HR, hazard ratio; PD‐L1, programmed death‐ligand 1; PFS, progression‐free survival; TPS, tumor proportion score; TTF‐1, thyroid transcription factor 1.